LETYBO® was FDA approved in 2024 for the temporary improvement of moderate to severe glabellar lines (frown lines between the brows) in adults. Clinical studies involving more than 1,200 patients demonstrated an established safety profile when administered by trained medical professionals.
As with all neuromodulators, side effects can occur and may include temporary redness, swelling, bruising, headache, or eyelid heaviness. Your provider will review your medical history and discuss whether LETYBO® is right for you.